Follow MuriPhys on LinkedInDurham, North Carolina, USA919.341.5445
MuriPhysTalk to a scientist

Research & scientific expertise

Cell line-derived xenograft models

Plan CDX research with MuriPhys, from tumor-cell and mouse-model selection through implantation, dosing, tumor monitoring, imaging and tissue analysis.

EXPLORE THE WORKOncology scientific leadershipCOMPARE THE SCOPEDelivery & pricingUSE THE PLANNING TOOLIn Vivo Study Planner

Cell line-derived xenograft (CDX) models use human tumor cell lines implanted into immunodeficient mice. Studies can measure tumor growth, treatment response and pharmacodynamic changes. MuriPhys supports subcutaneous and orthotopic implantation, IV, IM and SC dosing, caliper measurements and in vivo imaging. We select the cell line, mouse strain and endpoints according to the treatment question.

Models & cell lines

Solid Tumor Xenograft Models

Breast Cancer

MDA-MB-231 (TNBC, highly metastatic)

MCF-7 (ER+, PR+, luminal A subtype)

T47D (ER+, PR+, luminal B subtype)

Non-Small Cell Lung Cancer (NSCLC)

A549 (KRAS mutant, adenocarcinoma)

H1975 (EGFR T790M mutant, resistant to 1st-gen TKIs)

H1299 (p53-null, metastatic potential)

Colorectal Cancer

HCT116 (KRAS mutant, MSI+)

SW620 (metastatic colorectal cancer model)

HT-29 (BRAF V600E mutant, chemoresistant)

Pancreatic Cancer

PANC-1 (KRAS mutant, mesenchymal phenotype)

MiaPaCa-2 (KRAS mutant, p53 mutant, highly aggressive)

AsPC-1 (metastatic potential)

Brain Tumor

U87MG (glioblastoma, limited invasion capacity)

U251 (astrocytoma-derived, high proliferation)

DAOY (medulloblastoma, pediatric brain cancer)

Prostate Cancer

LNCaP (androgen-sensitive, PSA-producing)

DU145 (androgen-independent, metastatic potential)

PC-3 (highly aggressive, androgen receptor-negative)

Hematologic Cancer Xenograft Models

Leukemia Xenograft Models

Acute Myeloid Leukemia (AML)

  • MV4-11 (FLT3-ITD mutant)
  • HL-60 (differentiation-sensitive, ATRA-responsive)
  • KG-1 (primitive leukemic stem cell-like)

Acute Lymphoblastic Leukemia (ALL)

  • Nalm-6 (B-ALL, p53 wild-type)
  • MOLT-4 (T-ALL, highly proliferative)

Chronic Myeloid Leukemia (CML)

  • K562 (BCR-ABL1 fusion, imatinib-sensitive)

Lymphoma Xenograft Models

Diffuse Large B-Cell Lymphoma (DLBCL)

  • SU-DHL-4 (ABC subtype, NF-κB pathway activation)
  • OCI-LY3 (activated B-cell-like, MYD88 mutant)

Hodgkin Lymphoma (HL) Models

  • L428 (classical HL, CD30+)
  • KM-H2 (brentuximab vedotin-sensitive)

Multiple Myeloma Xenograft Models

  • MI-8226 (bortezomib-sensitive, IgG lambda secretion)

Drug administration & repeat dosing

We specialize in the following routes of administration:

Administration routes include intravenous (IV), intramuscular (IM), subcutaneous (SC), intrathecal (IT), intraperitoneal (IP), oral gavage and topical delivery, with slow or continuous infusion where appropriate.

Repeat dosing can be scheduled to assess treatment effects over time.

Cell-line quality control

Cell-line quality control includes mycoplasma testing to identify contamination. The testing plan, cell identity checks and acceptance criteria are defined for the study and documented with the work.

Discuss the tumor model, treatment strategy, readouts and study stage with our oncology team. We will work with you to define the methods, controls, deliverables, timing and budget.

Share this page
Share on LinkedInFollow MuriPhys

Discuss your study

Bring us your research question. We’ll help you work out the next step.

Discuss your project